[ad_1]
The American company Moderna announced that the complete results of the latest clinical trial have confirmed an efficacy of 94.1% of its anti-COVID-19 vaccine and will request emergency authorization from both the Food and Drug Administration (FDA) in the United States, as well as the European Medicines Agency (EMA), informs Agepres.
Two weeks ago, the American company Moderna’s anti-COVID-19 vaccine was declared 95% effective, according to preliminary data. No severe form of the disease occurred in the group of participants who were vaccinated.
The representatives of Moderna announced that they have already started the processes of analysis of their vaccine by the EMA, but also the procedures with the regulatory authorities of the drug market in Canada, Switzerland, Great Britain, Israel and Singapore, in order to streamline authorization procedures.
At the same time, Moderna published the results of its phase 3 COVE clinical study, conducted in 30,000 participants, which shows that the vaccine it developed is 94.1% efficient in preventing COVID-19 infection.
With its focus on Monday, Moderna will become the world’s first pharmaceutical company to formally request an EU vaccine against COVID-19.
Last week, the President of the European Commission, Ursula von der Leyen, announced that the EU had signed a contract with Moderna to buy up to 160 million doses of vaccine.
The contract provides for an initial delivery of 80 million doses and an option for another 80 million doses to be delivered at a later date.
Moderna representatives believe that this vaccine could be delivered to the EU in December at the earliest, if it is approved by the European Medicines Agency.
Publisher: ML
